Format

Send to

Choose Destination
Clin Immunol. 2006 Jan;118(1):35-41. Epub 2005 Sep 15.

B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis.

Author information

1
TolerGenics, Inc. 9610 Medical Center Dr. Suite 230, Rockville, MD 20850, USA. liang@tolergenics.com

Erratum in

  • Clin Immunol. 2006 Sep;120(3):357. Mattapallil, Mary [added]; Caspi, Rachel [added].

Abstract

Uveitis is an important autoimmune disease affecting an estimated 2.3 million Americans. This disease is manifested by inflammation of the retina mediated by the infiltration of T lymphocytes that recognize "S-Antigen" (S-Ag). Current therapies involve the life-long use of immunosuppressive drugs, including steroids. The ability to induce specific tolerance to S-Ag would be desirable and allow patients to be weaned off of steroid therapy. In this study, we determined that S-Ag-Ig retroviral vector was capable of preventing EAU (experimental autoimmune uveoretinitis) in Lewis rats induced by immunization with bovine S-Ag (BoS-Ag). Importantly, B-cell delivered gene therapy with S-Ag-Ig can ameliorate ongoing EAU when the treatment was initiated after rats had been immunized. Furthermore, we have successfully induced tolerance in HLA-DR3 transgenic mice with respect to the T-cell proliferative response. These results demonstrate proof of principle for future efforts to develop this approach for clinical application in patients with uveoretinitis.

PMID:
16168712
DOI:
10.1016/j.clim.2005.08.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center